Citi retains its sell call with a target price of ₹1,040, and BofA retains its accumulate recommendation with a target price of ₹1,480, compared with an earlier target of ₹1,500
SENSEX 76,515.80
NIFTY 23,950.20
CRUDEOIL 8,559.00
+ 149.00
GOLD 145,126.00
Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged…
The Sensex declined more than 400 points and the Nifty slipped below 24,100 in early trade amid higher crude oil prices and…
Dr Reddys shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69%…
India Business News: Morgan Stanley maintained equal-weight on Dr Reddy’s Labs with the target price at Rs 1,215 (against Rs…
Indian shares drop as oil prices surge and Asian market sell-offs dampen investor sentiment amid rising US rate hike fears.
Aurobindo Pharma surpasses Dr Reddy's in FY26 revenue, becoming the second-largest Indian pharma company.
